People · Operator
Named in public records as an officer, director or promoter · active 2020–2025 · Biotechnology, Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Monte Rosa Therapeutics, Inc. | — | Biotechnology | Series C | $143.0M | $3.0B | 2020 |
| FORE US Bio Inc. | — | Biotechnology | Series C | $99.5M | $243.5M | 2023 |
| CHARM Therapeutics Inc. | — | Pharma | Series B | $87.0M | $77.3M | 2025 |
Kim Blackwell at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Kim Blackwell on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Ali Behbahani | 1 | 17 |
| Rishi Gupta | 1 | 12 |
| BRADLEY BOLZON | 1 | 10 |
| Briggs Morrison | 1 | 8 |
| Erez Chimovits | 1 | 7 |
| Gary Glick | 1 | 7 |
| Michal Silverberg | 1 | 7 |
| Dieter Weinand | 1 | 4 |
| Alexander Mayweg | 1 | 4 |
| Chandra Leo | 1 | 3 |
| Markus Warmuth | 1 | 3 |
| William Hinshaw | 1 | 2 |
| Chandra P. Leo | 1 | 2 |
| Meenu Chhabra Karson | 1 | 2 |
| Roberto De Ponti | 1 | 2 |
| Nihal Sinha | 1 | 2 |
| Christine P. Siu | 1 | 2 |
| Michael Byrnes | 1 | 2 |
| Giovanni Mariggi | 1 | 2 |
| Matthew Foy | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.